We finally found that CD96 was negatively associated with CTNNB1 mutation and speculated that CTNNB1 may modulate NK cells by affecting CD96. Our research proposed a new underlying association between CTNNB1 mutation and immunotherapy in HCC, which may help in improving the efficacy of immunotherapy in HCC patients. Here, CD96 is linked to hepatocellular carcinoma.